drugset / Trial / NCT03556592
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: * 14 weeks of treatment with tralokinumab * a single dose of tralokinumab
Timeline
- Start
- 2018-08-13
- Primary completion
- 2020-03-16
- Completion
- 2020-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | 100 mg | Oral |
| Subject | Metoprolol | Other / unclassified | 100 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Omeprazole | Other / unclassified | 20 mg | Oral |
| Subject | Tralokinumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Warfarin | Small molecule | 10 mg | Oral |